Voyager Therapeutics, Inc. (VYGR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Voyager Therapeutics, Inc. reported revenue of $40.37M, down 49.5% from the prior year. The company ran a net loss, with a net margin of -296.5%. It held $252.28M in total assets against $56.20M in total liabilities.
Key ratios (FY2025)
-326.6%
Operating margin
-296.5%
Net margin
-61.1%
Return on equity
-49.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.37M | $80.00M | $250.01M | $40.91M | $37.41M | $171.13M | $104.39M | $7.62M | $10.13M | $14.22M |
| Operating Income | -$131.84M | -$83.29M | $122.01M | -$50.84M | -$73.62M | $27.38M | -$51.68M | -$91.09M | -$71.86M | -$41.30M |
| Net Income | -$119.72M | -$65.00M | $132.33M | -$46.41M | -$71.20M | $36.74M | -$43.60M | -$88.29M | -$70.70M | -$40.19M |
| EPS (Diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 | $-1.21 | $-2.75 | — | — |
| Total Assets | $252.28M | $393.05M | $351.28M | $159.36M | $193.85M | $261.58M | $354.76M | $177.03M | $184.48M | $189.57M |
| Total Liabilities | $56.20M | $93.29M | $114.96M | $100.34M | $98.80M | $107.26M | $255.25M | $130.58M | $50.43M | $53.64M |
| Shareholders' Equity | $196.08M | $299.76M | $236.32M | $59.02M | $95.06M | $154.32M | $99.51M | $46.45M | $134.05M | $135.92M |
| Cash & Equivalents | $65.30M | $71.37M | $68.80M | $98.96M | $117.43M | $104.44M | $86.04M | $46.86M | $31.53M | $36.64M |
| Operating Cash Flow | -$132.47M | -$15.31M | $77.92M | -$12.51M | -$53.52M | -$96.72M | $48.67M | -$15.89M | -$61.35M | -$42.48M |
| Capital Expenditures | $2.60M | $3.52M | $3.26M | $2.49M | $1.61M | $12.10M | $7.72M | $4.30M | $3.98M | $5.03M |
| Shares Outstanding | 59.05M | 54.73M | 44.04M | 38.61M | 37.92M | 37.37M | 36.87M | 32.36M | 31.57M | 25.60M |
| Dividends Per Share | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — |